Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant
process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence
and mortality rates from NHL are highest in developed countries. While many patients with
aggressive NHL are curable with initial anthracycline-containing regimens, the majority of
patients will relapse or prove refractory to initial therapy. The prognosis of patients with
disease recurrence following a multidrug regimen is also limited. The current protocol is
designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive
Refractory Non-Hodgkin's Lymphoma.